Adam’s Take

Adam's Take Adam Feuerstein

STAT Plus: CytoDyn’s Covid-19 drug troubles escalate: Efficacy data are missing from study

Adam's Take Adam Feuerstein

STAT Plus: Moderna’s skyrocketing market value is an indictment of the U.S. Covid-19 response

Adam's Take Adam Feuerstein

STAT Plus: Applied Therapeutics amends investor deck, bolstering accusations made by anonymous critic

Adam's Take Adam Feuerstein

STAT Plus: FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility

Adam's Take Adam Feuerstein

STAT Plus: A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it

Adam's Take Adam Feuerstein

STAT Plus: ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress

Adam's Take Adam Feuerstein

STAT Plus: Moderna carries a big-boy market valuation now, so it shouldn’t act like a biotech penny stock

Adam's Take Adam Feuerstein

STAT Plus: With high hopes for its Covid-19 vaccine, Moderna stock value requires nearly mythical leap of faith

Adam's Take Adam Feuerstein

STAT Plus: CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed

Biotech Adam Feuerstein

STAT Plus: CytoDyn CEO made $12M from his stock sale, and his explanation raises more questions

Adam's Take Adam Feuerstein

STAT Plus: Without showing any data, CytoDyn touts treatment for Covid-19 as winner — while its CEO sells stock

Adam's Take Adam Feuerstein

STAT Plus: Aytu Bioscience capitalizes on coronavirus antibody test demand, but the good times won’t last

Adam's Take Adam Feuerstein

STAT Plus: Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence

Adam's Take Adam Feuerstein

STAT Plus: Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals

Adam's Take Adam Feuerstein

STAT Plus: Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’

Adam's Take Adam Feuerstein

STAT Plus: Biotech in the time of the coronavirus: With China returning to work, preclinical companies ramping back up

Adam's Take Adam Feuerstein

STAT Plus: Biotech in the time of the coronavirus: Stocks are down, but optimistic investors see opportunities ahead

Adam's Take Adam Feuerstein

STAT Plus: Biotech in the time of the coronavirus: Disruptions continue, but there’s some good news, too

Adam's Take Adam Feuerstein

STAT Plus: Biotech in the time of the coronavirus: A semi-regular column on the outbreak’s impact on drug makers

Adam's Take Adam Feuerstein

STAT Plus: Biotech, bracing for widespread coronavirus fallout, hopes for the best and prepares for the worst

Adam's Take Adam Feuerstein

STAT Plus: TG Therapeutics cops to another blood cancer drug trial delay, as excuses wear thin

Adam's Take Adam Feuerstein

STAT Plus: Allakos is running clinical trials in reverse, critics say, raising questions about its digestive disease drug

Adam's Take Adam Feuerstein

STAT Plus: ‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug

Adam's Take Adam Feuerstein

STAT Plus: Investor impatience with Gilead reclamation project sparks acquisition chatter

Adam's Take Adam Feuerstein

STAT Plus: If biotech had a Mount Rushmore, whose heads would you chisel in the granite?

Adam's Take Adam Feuerstein

STAT Plus: As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

Adam's Take Adam Feuerstein

STAT Plus: The truth about JPM: Less is more

Adam's Take Adam Feuerstein

STAT Plus: All talk, no M&A makes for a down JPM Day

Adam's Take Adam Feuerstein

STAT Plus: Two days into the ‘real’ start of 2020 and all those expected biotech buyouts are still MIA